STUDY EFFECTIVENESS OF TADALAFIL IN THE MANAGEMENT OF THE LOWER THIRD URETERAL STONES WITH SIZE 10 MM OR LESS

Kawa Mousa Daoud* and Mohammed Kanaan

ABSTRACT

Study Aim: Study effectiveness of Tadalafil in the management of the lower third ureteral stones with size 10 mm or less. Material and Methods: The study sample consisted of (70) with a radiologically proven distal ureteral stone and were eligible for inclusion in this study and were systematically distributed into two groups: Group A: receive treatment with Tadalafil 5 mg once aday for 14 days. Group B: receive treatment with Placebo for 14 days. Tramadol or diclofenac potassium was also prescribed for pain relief. Results: The research sample comprised 70 patients, exhibiting a history of 5-10 mm lower ureteral stones confirmed radiologically during the period of 2023-2024. The patients' ages ranged from 19 to 69 years, with a mean age of 45.32±6.4 years. Stone sizes varied between 5 and 9.8 mm, Within the study sample, 75.7% were male (53 patients) and 24.3% were female (17 patients), Additionally, 72.9% (51 patients) had right-sided stones, In Group A, the average stone size was 6.9±1.9 mm, with sizes ranging from 5-9.8 mm; whereas, in Group B, the average stone size was 6.3±1.4 mm, with sizes between 5.3-9.1 mm. The average time for stone shedding in Group A was 5.8±1.8 days, with a range of 4-7 days. Conversely, Group B had an average shedding time of 9.66±2.6 days, with a range of 8-12 days. The stone shedding rate during the two-week follow-up period was 80% (28 patients) in Group A, while Group B recorded a shedding rate of 62.8% (22 patients).

Keywords: Stones, urolithiasis, Tadalafil.